IGHG3 and HIV-1 infection: In a recent comparison of the immune responses resulting from the partially effective clinical RV144 HIV-1 trial and the ineffective VAX003 trial, it was shown that HIV-1–specific IgG3 antibodies were correlated with decreased risk of HIV-1 infection in the RV144 trial.